Dominique Tersago

Chief Tech/Sci/R&D Officer bij CANTARGIA AB

Vermogen: - $ op 31-03-2024

62 jaar

Health Technology

Consumer Services

Actieve functies van Dominique Tersago

Bedrijven	Functie	Begin	Einde
CANTARGIA AB	Chief Tech/Sci/R&D Officer	01-08-2022	-

Bedrijven	Functie	Begin	Einde
Exevir Bio BV Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.	Chief Tech/Sci/R&D Officer	01-07-2020	01-07-2022
Highlight Therapeutics SL Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain.	Chief Tech/Sci/R&D Officer	01-04-2017	01-03-2020
ABLYNX	Chief Tech/Sci/R&D Officer	01-07-2013	01-11-2015

University of Antwerp

Doctorate Degree

Internationaal

Operationeel

Chief Tech/Sci/R&D Officer	4
Doctorate Degree	1

Sectoraal

Health Technology	5
Consumer Services	2

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	1
CANTARGIA AB	Health Technology

Bedrijven in privébezit	3
Ablynx NV Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium.	Health Technology
Highlight Therapeutics SL Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain.	Health Technology
Exevir Bio BV Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.	Health Technology